Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 9/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CASP2 | P42575 | 1/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.36 |
| ▸ | MMP8 | P22894 | 1/20 | 0.36 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.36 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.36 |
| ▸ | NAAA | Q02083 | 1/20 | 0.36 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15775180 | 0.83 | EPHX1 (0.40) | EPHX1MMP8 | |
| SCHEMBL8744908 | 0.81 | CHRNB2 (0.35) | — | |
| SCHEMBL7684377 | 0.79 | EPHX1 (0.47) | EPHX1CASP2DPP7EPHX2ZDHHC20 | |
| SCHEMBL11221492 | 0.74 | ZDHHC20 (0.47) | EPHX1SMN1; SMN2CASP2DPP7EPHX2 | |
| SCHEMBL7064442 | 0.74 | EPHX1 (0.42) | EPHX1CASP2 | |
| SCHEMBL4676338 | 0.72 | EPHX1 (0.50) | EPHX1CASP2DPP7EPHX2ZDHHC20 | |
| SCHEMBL5072049 | 0.70 | EPHX1 (0.41) | EPHX1CASP2EPHX2 | |
| SCHEMBL4373918 | 0.70 | EPHX1 (0.52) | EPHX1SMN1; SMN2CASP2DPP7MMP8 | |
| SCHEMBL24977105 | 0.68 | EPHX1 (0.55) | EPHX1SMN1; SMN2CASP2DPP7MMP8 | |
| SCHEMBL9474469 | 0.68 | EPHX1 (0.55) | EPHX1SMN1; SMN2CASP2DPP7MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6602901-B2 | Antidiabetic agents, obesity | NOVO NORDISK A/S (DK) | 2003-08-05 | — | — | US | disclosed |
| US-20010031786-A1 | Compounds useful in the treatment of conditions mediated by peroxisome proliferator-activated receptors (PPAR) | JEPPESEN LONE (DK) | 2001-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031786-A1 | Compounds useful in the treatment of conditions mediated by peroxisome proliferator-activated receptors (PPAR) | PPARG, PPARA, PPARD | EPHX1 1559/4885SMN1; SMN2 3676/4885CASP2 3876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.